Holen Sie sich die Stockscreener-App
87.27
0.61%
-0.54
Handel nachbörslich:
87.27
Schlusskurs vom Vortag:
$87.81
Offen:
$88.1
24-Stunden-Volumen:
388.63K
Relative Volume:
0.54
Marktkapitalisierung:
$5.55B
Einnahmen:
$136.86M
Nettoeinkommen (Verlust:
$-168.69M
KGV:
-31.06
EPS:
-2.81
Netto-Cashflow:
$-113.49M
1W Leistung:
-3.76%
1M Leistung:
+37.09%
6M Leistung:
+51.04%
1J Leistung:
+76.95%
1-Tages-Spanne:
$86.75
$88.36
1-Wochen-Bereich:
$86.75
$91.39
52-Wochen-Spanne:
$40.61
$94.80
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Firmenname
Rhythm Pharmaceuticals Inc
Sektor
Branche
Telefon
857-264-4280
Adresse
222 BERKELEY STREET, BOSTON, MA
Vergleichen Sie RYTM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
87.27 | 5.79B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-07-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-05 | Fortgesetzt | Stifel | Buy |
| 2025-01-02 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-21 | Eingeleitet | Guggenheim | Buy |
| 2024-09-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-08-08 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Bestätigt | Needham | Buy |
| 2022-03-02 | Fortgesetzt | Stifel | Buy |
| 2022-02-17 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Fortgesetzt | Goldman | Neutral |
| 2021-08-04 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-01-08 | Eingeleitet | Goldman | Sell |
| 2019-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2019-07-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-03-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2018-06-25 | Bestätigt | Needham | Buy |
| 2018-06-15 | Bestätigt | Needham | Buy |
| 2017-10-30 | Eingeleitet | BofA/Merrill | Buy |
| 2017-10-30 | Eingeleitet | Needham | Buy |
Alle ansehen
Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten
Rhythm Pharmaceuticals Inc. Stock Analysis and ForecastHigh-yield growth strategies - Autocar Professional
Is Rhythm Pharmaceuticals Inc. a good long term investmentMarket-leading growth rates - jammulinksnews.com
Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 - GlobeNewswire
Rhythm Pharmaceuticals Announces Q2 Earnings Date and Major Conference Appearance - Stock Titan
What analysts say about Rhythm Pharmaceuticals Inc. stockTremendous growth potential - jammulinksnews.com
What drives Rhythm Pharmaceuticals Inc. stock priceConsistently outstanding ROI - jammulinksnews.com
Should You Invest in This Under-the-Radar Weight Loss Stock? - Yahoo Finance
Rhythm Pharmaceuticals prices $175M stock offering - MSN
Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity - MSN
Why Rhythm Pharmaceuticals Inc. stock is on top investor watchlistsMoney Making Low Risk Plans - beatles.ru
Rhythm Pharmaceuticals Q1 2025 Earnings: IMCIVREE Sales Reach $37.7M, Inventory Impact Affects Revenue, Cash on Hand Reaches $314.5M - AInvest
Rhythm Pharmaceuticals CFO Sells 42,120 Shares - AInvest
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 10 Analysts - Nasdaq
Canaccord Genuity raises Rhythm Pharmaceuticals stock price target on obesity treatment potential - Investing.com Canada
(RYTM) Investment Analysis - news.stocktradersdaily.com
Rhythm Pharmaceuticals stock price target raised to $109 from $95 at BofA - Investing.com Canada
Rhythm Pharma gains as mid-stage trial for rare form of obesity succeeds - MSN
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given a $110.00 Price Target by Oppenheimer Analysts - MarketBeat
The week in pharma: action, reaction and insight – week to July 11 - The Pharma Letter
Rhythm Pharmaceuticals: MC4R Agonists Poised to Transform Obesity Treatment and Drive Market Leadership - AInvest
Rhythm Pharmaceuticals announces public offering of common stock - MSN
Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar? - MSN
Rhythm Pharmaceuticals price target raised to $95 from $72 at Needham - MSN
Rhythm Pharmaceuticals' MC4R Agonists: A Rare Disease Breakthrough with Massive Upside - AInvest
Rhythm Pharmaceuticals: Pioneering a New Era in Rare Obesity Therapies with MC4R Agonists - AInvest
Rhythm Pharmaceuticals says Phase 2 signal trial shows bivamlegon reduces BMI in hypothalamic obesity - MarketScreener
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 - GlobeNewswire
Rhythm Pharmaceuticals Shares Jump Following Promising Phase 2 Data for Obesity Drug - MSN
Rhythm Pharmaceuticals' Insider Sales: A Pre-Planned Strategy or a Signal for Investors? - AInvest
Rhythm Pharmaceuticals: Insider Sales and Equity Offering Signal Mixed Signals for Investors - AInvest
Rhythm Pharmaceuticals Insider Sales and I-MAB's Capital Raise: Navigating Dilution Risks and Confidence Signals - AInvest
Rhythm Pharmaceuticals: Insider Selling and Valuation in a High-Stakes Biotech Landscape - AInvest
Top 3 Trending Stocks: Ultragenyx Pharmaceutical, Rhythm Pharmaceuticals, and Nurix Therapeutics - AInvest
Rhythm Pharmaceuticals Announces Stock Offering Agreement - TipRanks
RYTM raises $188.7M via 2.37M-share offering at $85 | RYTM SEC FilingForm 8-K - Stock Titan
Rhythm Pharmaceuticals price target raised to $95 from $73 at BofA - MSN
Rhythm Pharmaceuticals (RYTM) Explores New Treatment for Hypotha - GuruFocus
Rhythm Pharmaceuticals' Bivamelagon: A Path to Dominating Acquired Hypothalamic Obesity and Driving Stock Gains - AInvest
Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market (RYTM) - Seeking Alpha
Rhythm Pharmaceuticals (RYTM) Gets Price Target Boost from Oppen - GuruFocus
Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity - MSN
Rhythm Pharmaceuticals prices upsized public offering at $85 per share - Investing.com India
Rhythm Pharmaceuticals (RYTM) Target Price Raised by B of A Secu - GuruFocus
RYTM Stock Rises On Upbeat Acquired Hypothalamic Obesity Study Data - Barchart.com
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data - The Globe and Mail
Oppenheimer raises Rhythm Pharmaceuticals stock price target to $110 By Investing.com - Investing.com Canada
Finanzdaten der Rhythm Pharmaceuticals Inc-Aktie (RYTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rhythm Pharmaceuticals Inc-Aktie (RYTM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Smith Hunter C | Chief Financial Officer |
Jul 09 '25 |
Sale |
80.48 |
42,120 |
3,389,756 |
116,915 |
| Shulman Joseph | Chief Technical Officer |
Jul 09 '25 |
Option Exercise |
6.80 |
7,969 |
54,189 |
16,478 |
| Shulman Joseph | Chief Technical Officer |
Jul 09 '25 |
Sale |
77.78 |
7,969 |
619,851 |
8,509 |
| German Christopher Paul | Corporate Controller & CAO |
Jul 09 '25 |
Option Exercise |
27.29 |
2,850 |
77,786 |
4,739 |
| German Christopher Paul | Corporate Controller & CAO |
Jul 09 '25 |
Sale |
80.75 |
3,817 |
308,217 |
922 |
| Cramer Pamela J. | Chief Human Resources Officer |
Jul 09 '25 |
Option Exercise |
13.43 |
15,572 |
209,153 |
34,781 |
| Cramer Pamela J. | Chief Human Resources Officer |
Jul 09 '25 |
Sale |
77.13 |
15,572 |
1,201,062 |
19,209 |
3.32%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):